Literature DB >> 2582332

Chorioretinal and choriovitreal neovascularization after photocoagulation for proliferative diabetic retinopathy. A clinicopathologic correlation.

I Wallow, K Johns, P Barry, S Chandra, C Bindley.   

Abstract

A patient with proliferative diabetic retinopathy was treated by panretinal and focal photocoagulation. Later, he developed one area of clinically diagnosed chorioretinal and choriovitreal neovascularization (CNV), neovascular glaucoma, and a blind painful eye necessitating enucleation. Clinicopathologic correlations of this eye including fundus photography, fluorescein angiography, light and electron microscopy are reported. Histopathologic examination revealed three areas of CNV, suggesting that some CNV may go undetected clinically also in other cases and thus may occur more frequently than evident from the literature. Our CNV occurred at sites of focal treatment. Retreatment of one area was unsuccessful. Choriovitreal neovascularization passed through discontinuities of Bruch's membrane into the retina and showed fenestrae of the endothelial cells. Endothelial fenestrae may account for the profuse fluorescein leakage seen clinically in CNV.

Entities:  

Mesh:

Year:  1985        PMID: 2582332     DOI: 10.1016/s0161-6420(85)34012-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Iatrogenic choroidal neovascularisation following argon laser photocoagulation for choroidal malignant melanoma.

Authors:  Z I Currie; I G Rennie; J F Talbot
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-04       Impact factor: 3.117

2.  Idiopathic choriovitreal membrane--a case report.

Authors:  S H Sinclair; B D Salmenson
Journal:  Br J Ophthalmol       Date:  1992-09       Impact factor: 4.638

3.  Choriovitreal ingrowth of a large choroidal vessel after scatter retinal photocoagulation.

Authors:  Umesh C Behera; Rohit Ramesh Modi
Journal:  Oman J Ophthalmol       Date:  2015 Jan-Apr

4.  Hsp90 inhibition sensitizes DLBCL cells to cisplatin.

Authors:  Linnéa Schmidt; Issa Ismail Issa; Hulda Haraldsdóttir; Jonas Laugård Hald; Alexander Schmitz; Hanne Due; Karen Dybkær
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-21       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.